High throughput selection and characterization of aptamers

艾灵顿实验室将采用高通量、自动化的选择方法 得克萨斯大学奥斯汀分校开发针对HIV-1 Rev、Tat、Reverse的适配子 转录酶、核糖核酸酶H和RRE。适配子将以该公司为特征 并在Prasad病毒感染的细胞培养模型中进行了检测 阿尔伯特·爱因斯坦医学院的实验室，以及约翰逊大学的动物模型 哈佛大学的实验室。选定的适配子还将用于生成用于映射的芯片 用于表位和抗药性突变的检测。病毒抗药性的研究进展 将通过对已获得的蛋白质进行重新选择来进一步解决 抗药性突变。最终，这些选择实验应该会加强 开发高效的艾滋病基因疗法，并将提供独特的 对病毒抗药性进化的洞察。

High-throughput, automated selection methods will be employed by the Ellington lab at the University of Texas at Austin to generate aptamers against HIV-1 Rev, Tat, reverse transcriptase, Rnase H, and the RRE. Aptamers will be characterized by the company Accacia, and subsequently assayed in cell culture models of viral infection by the Prasad lab at the Albert Einstein College of Medicine, as well as in animal models by the Johnson lab at Harvard. The selected aptamers will also be used to generate chips for mapping epitopes and for the detection of resistance mutants. The development of viral resistance will be further addressed by conducting re-selections against proteins that have acquired resistance mutations. Ultimately, these selection experiments should potentiate the development of highly efficacious gene therapies for AIDS and will also provide unique insights into the evolution of viral resistance.